Turkiye Klinikleri Journal of Internal Medicine

.: REVIEW
Akut Pankreatit Tedavisi
Treatment of Acute Pancreatitis
Ömer Burcak BİNİCİERa, Damla Çağla PATIRb
aSağlık Bilimleri Üniversitesi Tepecik Eğitim ve Araştırma Hastanesi, Gastroenteroloji Bölümü, İzmir, TÜRKİYE
bSağlık Bilimleri Üniversitesi Tepecik Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İzmir, TÜRKİYE
Turkiye Klinikleri J Intern Med. 2021;6(1):22-38
doi: 10.5336/intermed.2020-75948
Article Language: TR
Full Text
ÖZET
 Akut pankreatit (AP) artan yaşam süresi, obezite, alkol kullanımı, hiperlipidemi, ilaç kullanımı ve tanısal yöntemlerin kullanımının artmasına bağlı insidansı artış gösteren önemli bir gastrointestinal klinik hadisedir. Son yıllarda artan insidansa rağmen erken tanı yöntemleri ve hastalığın patofizyolojisinin anlaşılması ile hastanede yatış süresi, maliyet ve mortalite oranlarında azalmalar görülmektedir. Bunun yanı sıra, mortalite oranlarının altta yatan etiyolojiden (safra taşı, alkol, hipertrigliseridemi, vs.) bağımsız olduğu, hastalık şiddeti ve 48 saatten uzun süren organ yetmezliği tablosu ile yakın ilişkili olduğu görülmektedir. AP hastalarının ilk sıra tedavi basamakları; sıvı replasmanı, ağrı kontrolü ve beslenme desteğidir. Hastanın, agresif sıvı replasmanına engel olacak kardiyovasküler, renal veya diğer ciddi başka komorbid bir hastalığı yoksa tüm hastalara saatte 5-10 mL/kg'dan izotonik kristaloid çözelti (normal salin veya ringer laktat çözeltisi) ile hidrasyon sağlanması önemlidir. Hastaların, saatlik idrar çıkışı >0,5-1 cc/ kg/ saat olacak şekilde takip edilmeli ve sıvı replasmanı buna göre ayarlanmalıdır. AP'li hastalarda, ağrının kontrol altına alınması, hemodinamik instabilite açısından da önem arz etmektedir. AP tanılı hastalarda, enteral beslenmeye mümkün olduğunca erken başlanması, bağırsak bariyeri üzerinde koruyucu etkisi ve bakteriyel translokasyonun önlemesi nedeniyle önemlidir. Bu makalede, AP tanısı alan hastaların tedavi yöntemleri güncel literatür eşliğinde özetlenmiştir.

Anahtar Kelimeler: Akut pankreatit; sıvı replasmanı; ağrı kontrolü; beslenme
ABSTRACT
 Acute pancreatitis is an important gastrointestinal condition with an increasing incidence due to improved life expectancy and more widespread availability of diagnostic methods as well as due to increased prevalence of obesity, alcohol use, hyperlipidemia, and drug use in communities. Despite this, a decline in hospitalization time, disease-related costs and mortality has been noted in recent years owing to earlier diagnosis and better understanding of the pathophysiology of the disease. Furthermore, it has been established that the mortality rates are independent of the underlying etiology (gallstone, alcohol, hypertriglyceridemia, etc.), and are closely related to disease severity and organ failure lasting more than 48 hours. The initial management of acute pancreatitis should include fluid replacement, pain control, and nutritional support. In the absence of cardiovascular, renal or other serious comorbid conditions precluding aggressive fluid replacement, it is important to hydrate all patients with isotonic crystalloid solution (normal saline or ringer lactate solution) at a dose of 5-10 mL/kg per hour. Patients' hourly urine output should be monitored as to maintain it >0.5-1 cc/kg/hour and fluid replacement should be adjusted accordingly. Pain control in patients with acute pancreatitis is also critical in terms of hemodynamic instability. It is important to start enteral feeding as early as possible in these patients, to protect the intestinal barrier and to prevent bacterial translocation. In this article, the management strategies in patients diagnosed with acute pancreatitis are summarized in the light of current literature.

Keywords: Acute pancreatitis; fluid replacement; pain control; nutrition
REFERENCES:
  1. Singh VK, Bollen TL, Wu BU, Repas K, Maurer R, Yu S, et al. An assessment of the severity of interstitial pancreatitis. Clin Gastroenterol Hepatol. 2011;9(12):1098-103.[Crossref] [PubMed] 
  2. van Brunschot S, van Grinsven J, van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA, et al. Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. Lancet. 2018;391(10115):51-8.[PubMed] 
  3. Roberts SE, Morrison-Rees S, John A, Williams JG, Brown TH, Samuel DG, et al. The incidence and aetiology of acute pancreatitis across Europe. Pancreatology. 2017;17(2):155-65.[Crossref] [PubMed] 
  4. Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15;1416. Erratum in: Am J Gastroenterol. 2014;109(2):302.[Crossref] [PubMed] 
  5. Lankisch PG, Lowenfels AB, Maisonneuve P. What is the risk of alcoholic pancreatitis in heavy drinkers? Pancreas. 2002;25(4):411-2.[Crossref] [PubMed] 
  6. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330(17):1198-210.[Crossref] [PubMed] 
  7. James TW, Crockett SD. Management of acute pancreatitis in the first 72 hours. Curr Opin Gastroenterol. 2018;34(5):330-5.[Crossref] [PubMed] [PMC] 
  8. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003;36(1):54-62.[Crossref] [PubMed] 
  9. Fagenholz PJ, Castillo CF, Harris NS, Pelletier AJ, Camargo CA Jr. Increasing United States hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol. 2007;17(7):491-7.[Crossref] [PubMed] 
  10. Krishna SG, Kamboj AK, Hart PA, Hinton A, Conwell DL. The Changing Epidemiology of Acute Pancreatitis Hospitalizations: A Decade of Trends and the Impact of Chronic Pancreatitis. Pancreas. 2017;46(4):482-8.[Crossref] [PubMed] [PMC] 
  11. Gliem N, Ammer-Herrmenau C, Ellenrieder V, Neesse A. Management of Severe Acute Pancreatitis: An Update. Digestion. 2020:1-5.[Crossref] [PubMed] 
  12. Zorniak M, Beyer G, Mayerle J. Risk Stratification and Early Conservative Treatment of Acute Pancreatitis. Visc Med. 2019;35(2):82-9.[Crossref] [PubMed] [PMC] 
  13. Papachristou GI, Muddana V, Yadav D, O'Connell M, Sanders MK, Slivka A, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. Am J Gastroenterol. 2010;105(2):435-41; quiz 442.[Crossref] [PubMed] 
  14. Wu BU, Johannes RS, Sun X, Conwell DL, Banks PA. Early changes in blood urea nitrogen predict mortality in acute pancreatitis. Gastroenterology. 2009;137(1):129-35.[Crossref] [PubMed] 
  15. Guidelines for intensive care unit admission, discharge, and triage. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med. 1999;27(3):633-8.[Crossref] [PubMed] 
  16. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1-15.[Crossref] [PubMed] 
  17. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102-11.[Crossref] [PubMed] 
  18. Andersen AM, Novovic S, Ersbøll AK, Hansen MB. Mortality in alcohol and biliary acute pancreatitis. Pancreas. 2008;36(4):432-4.[Crossref] [PubMed] 
  19. Goyal H, Smith B, Bayer C, Rutherford C, Shelnut D. Differences in Severity and Outcomes Between Hypertriglyceridemia and Alcohol-Induced Pancreatitis. N Am J Med Sci. 2016;8(2):82-7.[Crossref] [PubMed] [PMC] 
  20. Gardner TB, Vege SS, Pearson RK, Chari ST. Fluid resuscitation in acute pancreatitis. Clin Gastroenterol Hepatol. 2008;6(10):1070-6.[Crossref] [PubMed] 
  21. Huh JH, Jeon H, Park SM, Choi E, Lee GS, Kim JW, et al. Diabetes Mellitus is Associated With Mortality in Acute Pancreatitis. J Clin Gastroenterol. 2018;52(2):178-83.[Crossref] [PubMed] 
  22. Wu BU, Johannes RS, Kurtz S, Banks PA. The impact of hospital-acquired infection on outcome in acute pancreatitis. Gastroenterology. 2008;135(3):816-20.[Crossref] [PubMed] [PMC] 
  23. Funnell IC, Bornman PC, Weakley SP, Terblanche J, Marks IN. Obesity: an important prognostic factor in acute pancreatitis. Br J Surg. 1993;80(4):484-6.[Crossref] [PubMed] 
  24. Heller SJ, Noordhoek E, Tenner SM, Ramagopal V, Abramowitz M, Hughes M, et al. Pleural effusion as a predictor of severity in acute pancreatitis. Pancreas. 1997;15(3):222-5.[Crossref] [PubMed] 
  25. Lankisch PG, Mahlke R, Blum T, Bruns A, Bruns D, Maisonneuve P, et al. Hemoconcentration: an early marker of severe and/or necrotizing pancreatitis? A critical appraisal. Am J Gastroenterol. 2001;96(7):2081-5.[Crossref] [PubMed] 
  26. Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ, Parks RW, et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg. 2006;93(6):738-44.[Crossref] [PubMed] 
  27. Faghih M, Fan C, Singh VK. New Advances in the Treatment of Acute Pancreatitis. Curr Treat Options Gastroenterol. 2019;17(1):146-60.[Crossref] [PubMed] 
  28. Haydock MD, Mittal A, Wilms HR, Phillips A, Petrov MS, Windsor JA, et al. Fluid therapy in acute pancreatitis: anybody's guess. Ann Surg. 2013;257(2):182-8.[Crossref] [PubMed] 
  29. Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, et al. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9(8):710-17.e1.[Crossref] [PubMed] 
  30. Vege SS, DiMagno MJ, Forsmark CE, Martel M, Barkun AN. Initial Medical Treatment of Acute Pancreatitis: American Gastroenterological Association Institute Technical Review. Gastroenterology. 2018;154(4):1103-39.[Crossref] [PubMed] 
  31. Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD, et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. Pancreas. 2011;40(8):1220-5.[Crossref] [PubMed] 
  32. Zhao G, Zhang JG, Wu HS, Tao J, Qin Q, Deng SC, et al. Effects of different resuscitation fluid on severe acute pancreatitis. World J Gastroenterol. 2013;19(13):2044-52.[Crossref] [PubMed] [PMC] 
  33. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018;154(4):1096-1101.[Crossref] [PubMed] 
  34. Wu BU, Conwell DL. Acute pancreatitis part I: approach to early management. Clin Gastroenterol Hepatol. 2010;8(5):410-6, quiz e56-8.[Crossref] [PubMed] 
  35. Brown A, Baillargeon JD, Hughes MD, Banks PA. Can fluid resuscitation prevent pancreatic necrosis in severe acute pancreatitis? Pancreatology. 2002;2(2):104-7.[Crossref] [PubMed] 
  36. Whitcomb DC, Muddana V, Langmead CJ, Houghton FD Jr, Guenther A, Eagon PK, et al. Angiopoietin-2, a regulator of vascular permeability in inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United States and Germany. Am J Gastroenterol. 2010;105(10):2287-92.[Crossref] [PubMed] 
  37. Basurto Ona X, Rigau Comas D, Urrutia G. Opioids for acute pancreatitis pain. Cochrane Database Syst Rev. 2013;(7):CD009179.[Crossref] [PubMed] 
  38. Gülen B, Dur A, Serinken M, Karcıoğlu Ö, Sönmez E. Pain treatment in patients with acute pancreatitis: A randomized controlled trial. Turk J Gastroenterol. 2016;27(2):192-6.[Crossref] [PubMed] 
  39. Meng W, Yuan J, Zhang C, Bai Z, Zhou W, Yan J, et al. Parenteral analgesics for pain relief in acute pancreatitis: a systematic review. Pancreatology. 2013;13(3):201-6.[Crossref] [PubMed] 
  40. Sadowski SM, Andres A, Morel P, Schiffer E, Frossard JL, Platon A, et al. Epidural anesthesia improves pancreatic perfusion and decreases the severity of acute pancreatitis. World J Gastroenterol. 2015;21(43):12448-56.[Crossref] [PubMed] [PMC] 
  41. Helm JF, Venu RP, Geenen JE, Hogan WJ, Dodds WJ, Toouli J, et al. Effects of morphine on the human sphincter of Oddi. Gut. 1988;29(10):1402-7.[Crossref] [PubMed] [PMC] 
  42. Lakananurak N, Gramlich L. Nutrition management in acute pancreatitis: Clinical practice consideration. World J Clin Cases. 2020;8(9):1561-73.[Crossref] [PubMed] [PMC] 
  43. Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. Clin Nutr. 2007;26(6):758-63.[Crossref] [PubMed] 
  44. Moraes JM, Felga GE, Chebli LA, Franco MB, Gomes CA, Gaburri PD, et al. A full solid diet as the initial meal in mild acute pancreatitis is safe and result in a shorter length of hospitalization: results from a prospective, randomized, controlled, double-blind clinical trial. J Clin Gastroenterol. 2010;44(7):517-22.[Crossref] [PubMed] 
  45. Uomo G, Manes G, Laccetti M, Cavallera A, Rabitti PG. Endoscopic sphincterotomy and recurrence of acute pancreatitis in gallstone patients considered unfit for surgery. Pancreas. 1997;14(1):28-31.[Crossref] [PubMed] 
  46. Welbourn CR, Beckly DE, Eyre-Brook IA. Endoscopic sphincterotomy without cholecystectomy for gall stone pancreatitis. Gut. 1995;37(1):119-20.[Crossref] [PubMed] [PMC] 
  47. Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest Endosc. 2015;81(1):143-9.e9.[Crossref] [PubMed] 
  48. Kubiliun NM, Adams MA, Akshintala VS, Conte ML, Cote GA, Cotton PB, et al; United States Cooperative for Outcomes Research in Endoscopy (USCORE). Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review. Clin Gastroenterol Hepatol. 2015;13(7):1231-9; quiz e70-1.[Crossref] [PubMed] 
  49. Vadalà di Prampero SF, Faleschini G, Panic N, Bulajic M. Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review. Eur J Gastroenterol Hepatol. 2016;28(12):1415-24.[Crossref] [PubMed] 
  50. Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007;66(6):1126-32.[Crossref] [PubMed] 
  51. Ishiwatari H, Urata T, Yasuda I, Matsusaki S, Hisai H, Kawakami H, et al. No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Dig Dis Sci. 2016;61(11):3292-3301.[Crossref] [PubMed] 
  52. Kato K, Shiba M, Kakiya Y, Maruyama H, Ominami M, Fukunaga S, et al. Celecoxib Oral Administration for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Randomized Prospective Trial. Pancreas. 2017;46(7):880-6.[Crossref] [PubMed] 
  53. Sagi SV, Schmidt S, Fogel E, Lehman GA, McHenry L, Sherman S, et al. Association of greater intravenous volume infusion with shorter hospitalization for patients with post-ERCP pancreatitis. J Gastroenterol Hepatol. 2014;29(6):1316-20.[Crossref] [PubMed] 
  54. Choi JH, Kim HJ, Lee BU, Kim TH, Song IH. Vigorous Periprocedural Hydration With Lactated Ringer's Solution Reduces the Risk of Pancreatitis After Retrograde Cholangiopancreatography in Hospitalized Patients. Clin Gastroenterol Hepatol. 2017;15(1):86-92.e1.[Crossref] [PubMed] 
  55. Park CH, Paik WH, Park ET, Shim CS, Lee TY, Kang C, et al. Aggressive intravenous hydration with lactated Ringer's solution for prevention of post-ERCP pancreatitis: a prospective randomized multicenter clinical trial. Endoscopy. 2018;50(4):378-85.[Crossref] [PubMed] 
  56. Wu D, Wan J, Xia L, Chen J, Zhu Y, Lu N, et al. The Efficiency of Aggressive Hydration With Lactated Ringer Solution for the Prevention of Post-ERCP Pancreatitis: A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2017;51(8):e68-e76.[Crossref] [PubMed] 
  57. Zhang ZF, Duan ZJ, Wang LX, Zhao G, Deng WG. Aggressive Hydration With Lactated Ringer Solution in Prevention of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis: A Meta-analysis of Randomized Controlled Trials. J Clin Gastroenterol. 2017;51(3):e17-e26.[Crossref] [PubMed] 
  58. Mok SRS, Ho HC, Shah P, Patel M, Gaughan JP, Elfant AB, et al. Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointest Endosc. 2017;85(5):1005-13.[Crossref] [PubMed] 
  59. Cao WL, Yan WS, Xiang XH, Chen K, Xia SH. Prevention effect of allopurinol on post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of prospective randomized controlled trials. PLoS One. 2014;9(9):e107350.[Crossref] [PubMed] [PMC] 
  60. Kwanngern K, Tiyapattanaputi P, Wanitpukdeedecha M, Navicharern P. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study. J Med Assoc Thai. 2005;88 Suppl 4:S42-5.[PubMed] 
  61. Li S, Cao G, Chen X, Wu T. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2012;24(5):477-81.[Crossref] [PubMed] 
  62. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc. 2002;55(4):470-5.[Crossref] [PubMed] 
  63. Shao LM, Chen QY, Chen MY, Cai JT. Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci. 2010;55(1):1-7.[Crossref] [PubMed] 
  64. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc. 2003;58(1):23-9.[Crossref] [PubMed] 
  65. Lenhart DK, Balthazar EJ. MDCT of acute mild (nonnecrotizing) pancreatitis: abdominal complications and fate of fluid collections. AJR Am J Roentgenol. 2008;190(3):643-9.[Crossref] [PubMed] 
  66. Dhaka N, Samanta J, Kochhar S, Kalra N, Appasani S, Manrai M, et al. Pancreatic fluid collections: What is the ideal imaging technique? World J Gastroenterol. 2015;21(48):13403-10.[Crossref] [PubMed] [PMC] 
  67. Morgan DE, Baron TH, Smith JK, Robbin ML, Kenney PJ. Pancreatic fluid collections prior to intervention: evaluation with MR imaging compared with CT and US. Radiology. 1997;203(3):773-8.[Crossref] [PubMed] 
  68. ASGE Standards of Practice Committee, Muthusamy VR, Chandrasekhara V, Acosta RD, Bruining DH, Chathadi KV, et al. The role of endoscopy in the diagnosis and treatment of inflammatory pancreatic fluid collections. Gastrointest Endosc. 2016;83(3):481-8.[Crossref] [PubMed] 
  69. Antillon MR, Shah RJ, Stiegmann G, Chen YK. Single-step EUS-guided transmural drainage of simple and complicated pancreatic pseudocysts. Gastrointest Endosc. 2006;63(6):797-803.[Crossref] [PubMed] 
  70. Hookey LC, Debroux S, Delhaye M, Arvanitakis M, Le Moine O, Devière J, et al. Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc. 2006;63(4):635-43.[Crossref] [PubMed] 
  71. Kahaleh M, Shami VM, Conaway MR, Tokar J, Rockoff T, De La Rue SA, et al. Endoscopic ultrasound drainage of pancreatic pseudocyst: a prospective comparison with conventional endoscopic drainage. Endoscopy. 2006;38(4):355-9.[Crossref] [PubMed] 
  72. Krüger M, Schneider AS, Manns MP, Meier PN. Endoscopic management of pancreatic pseudocysts or abscesses after an EUS-guided 1-step procedure for initial access. Gastrointest Endosc. 2006;63(3):409-16.[Crossref] [PubMed] 
  73. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. Radiology. 2002;223(3):603-13.[Crossref] [PubMed] 
  74. Baril NB, Ralls PW, Wren SM, Selby RR, Radin R, Parekh D, et al. Does an infected peripancreatic fluid collection or abscess mandate operation? Ann Surg. 2000;231(3):361-7.[Crossref] [PubMed] [PMC] 
  75. Ocampo C, Oría A, Zandalazini H, Silva W, Kohan G, Chiapetta L, et al. Treatment of acute pancreatic pseudocysts after severe acute pancreatitis. J Gastrointest Surg. 2007;11(3):357-63.[Crossref] [PubMed] 
  76. Freeny PC, Hauptmann E, Althaus SJ, Traverso LW, Sinanan M. Percutaneous CT-guided catheter drainage of infected acute necrotizing pancreatitis: techniques and results. AJR Am J Roentgenol. 1998;170(4):969-75.[Crossref] [PubMed] 
  77. Mortelé KJ, Girshman J, Szejnfeld D, Ashley SW, Erturk SM, Banks PA, et al. CT-guided percutaneous catheter drainage of acute necrotizing pancreatitis: clinical experience and observations in patients with sterile and infected necrosis. AJR Am J Roentgenol. 2009;192(1):110-6.[Crossref] [PubMed] 
  78. Traverso LW, Kozarek RA. Pancreatic necrosectomy: definitions and technique. J Gastrointest Surg. 2005;9(3):436-9.[Crossref] [PubMed] 
  79. Yasuda I, Takahashi K. Endoscopic management of walled-off pancreatic necrosis. Dig Endosc. 2020.[Crossref] [PubMed] 
  80. Chandrasekaran P, Gupta R, Shenvi S, Kang M, Rana SS, Singh R, et al. Prospective comparison of long term outcomes in patients with severe acute pancreatitis managed by operative and non operative measures. Pancreatology. 2015;15(5):478-84.[Crossref] [PubMed] 
  81. Chandran S, Efthymiou M, Kaffes A, Chen JW, Kwan V, Murray M, et al. Management of pancreatic collections with a novel endoscopically placed fully covered self-expandable metal stent: a national experience (with videos). Gastrointest Endosc. 2015;81(1):127-35.[Crossref] [PubMed] 
  82. Dhir V, Teoh AY, Bapat M, Bhandari S, Joshi N, Maydeo A, et al. EUS-guided pseudocyst drainage: prospective evaluation of early removal of fully covered self-expandable metal stents with pancreatic ductal stenting in selected patients. Gastrointest Endosc. 2015;82(4):650-7; quiz 718.e1-5.[Crossref] [PubMed] 
  83. Rinninella E, Kunda R, Dollhopf M, Sanchez-Yague A, Will U, Tarantino I, et al. EUS-guided drainage of pancreatic fluid collections using a novel lumen-apposing metal stent on an electrocautery-enhanced delivery system: a large retrospective study (with video). Gastrointest Endosc. 2015;82(6):1039-46.[Crossref] [PubMed] 
  84. Shah RJ, Shah JN, Waxman I, Kowalski TE, Sanchez-Yague A, Nieto J, et al. Safety and efficacy of endoscopic ultrasound-guided drainage of pancreatic fluid collections with lumen-apposing covered self-expanding metal stents. Clin Gastroenterol Hepatol. 2015;13(4):747-52.[Crossref] [PubMed] 
  85. Sharaiha RZ, Tyberg A, Khashab MA, Kumta NA, Karia K, Nieto J, et al. Endoscopic Therapy With Lumen-apposing Metal Stents Is Safe and Effective for Patients With Pancreatic Walled-off Necrosis. Clin Gastroenterol Hepatol. 2016;14(12):1797-1803.[Crossref] [PubMed] 
  86. Siddiqui AA, Adler DG, Nieto J, Shah JN, Binmoeller KF, Kane S, et al. EUS-guided drainage of peripancreatic fluid collections and necrosis by using a novel lumen-apposing stent: a large retrospective, multicenter U.S. experience (with videos). Gastrointest Endosc. 2016;83(4):699-707.[Crossref] [PubMed] 
  87. Nabi Z, Basha J, Reddy DN. Endoscopic management of pancreatic fluid collections-revisited. World J Gastroenterol. 2017;23(15):2660-72.[Crossref] [PubMed] [PMC] 
  88. Bang JY, Navaneethan U, Hasan MK, Sutton B, Hawes R, Varadarajulu S, et al. Non-superiority of lumen-apposing metal stents over plastic stents for drainage of walled-off necrosis in a randomised trial. Gut. 2019;68(7):1200-9.[Crossref] [PubMed] [PMC] 
  89. Haas B, Nathens AB. Surgical indications in acute pancreatitis. Curr Opin Crit Care. 2010;16(2):153-8.[Crossref] [PubMed] 
  90. Leppäniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.[Crossref] [PubMed] [PMC] 
  91. Banks PA, Freeman ML; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379-400.[Crossref] [PubMed] 
  92. Beger HG, Bittner R, Block S, Büchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology. 1986;91(2):433-8.[Crossref] [PubMed] 
  93. Bradley EL 3rd, Allen K. A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. Am J Surg. 1991;161(1):19-24; discussion 24-5.[Crossref] [PubMed] 
  94. Haney CM, Kowalewski KF, Schmidt MW, Koschny R, Felinska EA, Kalkum E, et al. Endoscopic versus surgical treatment for infected necrotizing pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Surg Endosc. 2020;34(6):2429-2444.[Crossref] [PubMed] [PMC] 
  95. Kylanpaa L, Rakonczay Z Jr, O'Reilly DA. The clinical course of acute pancreatitis and the inflammatory mediators that drive it. Int J Inflam. 2012;2012:360685.[Crossref] [PubMed] [PMC] 
  96. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2002;9(4):401-10.[Crossref] [PubMed] 
  97. Baron TH, Morgan DE. Endoscopic transgastric irrigation tube placement via PEG for debridement of organized pancreatic necrosis. Gastrointest Endosc. 1999;50(4):574-7.[Crossref] [PubMed] 
  98. Clancy TE, Ashley SW. Current management of necrotizing pancreatitis. Adv Surg. 2002;36:103-21.[PubMed] 
  99. Nadkarni NA, Khanna S, Vege SS. Splanchnic venous thrombosis and pancreatitis. Pancreas. 2013;42(6):924-31.[Crossref] [PubMed] 
  100. Heider TR, Azeem S, Galanko JA, Behrns KE. The natural history of pancreatitis-induced splenic vein thrombosis. Ann Surg. 2004;239(6):876-80; discussion 880-2.[Crossref] [PubMed] [PMC] 
  101. Radenkovic DV, Bajec D, Ivancevic N, Bumbasirevic V, Milic N, Jeremic V, et al. Decompressive laparotomy with temporary abdominal closure versus percutaneous puncture with placement of abdominal catheter in patients with abdominal compartment syndrome during acute pancreatitis: background and design of multicenter, randomised, controlled study. BMC Surg. 2010;10:22.[Crossref] [PubMed] [PMC] 
  102. De Waele JJ, De Laet I, Kirkpatrick AW, Hoste E. Intra-abdominal Hypertension and Abdominal Compartment Syndrome. Am J Kidney Dis. 2011;57(1):159-69.[Crossref] [PubMed] 
  103. Das SL, Singh PP, Phillips AR, Murphy R, Windsor JA, Petrov MS, et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2014;63(5):818-31.[Crossref] [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com